Global Prostate Cancer Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)

Table of Contents

1. Executive Summary

2. Introduction
2.1 Cancer: An Overview
2.1.1 Introduction
2.1.2 Types of Cancer
2.2 Prostate Cancer: An Overview
2.2.1 Introduction
2.2.2 Prostate Cancer Symptoms
2.2.3 Stages of Prostate Cancer
2.2.4 Types of Prostate Cancer
2.2.5 Treatments Available

3. Global Market Analysis
3.1 Global Prostate Cancer Market: An Analysis
3.1.1 Global Prostate Cancer Drug Market by Value
3.1.2 Global Prostate Cancer Drug Market by Country (US, China, ROW)
3.1.3 Global Prostate Cancer Market by Drugs (Enzalutamide, Abiraterone acetate, Leuprorelin, Goserelin, Cabazitaxel, Bicalutamide, Radium 223 dichloride, others)
3.2 Global Prostate Cancer Market: Drug Analysis
3.2.1 Global Enzalutamide Market by Value
3.2.2 Global Abiraterone acetate Market by Value
3.2.3 Global Leuprorelin Market by Value
3.2.4 Global Goserelin Market by Value
3.2.5 Global Cabazitaxel Market by Value
3.2.6 Global Bicalutamide Market by Value
3.2.7 Global Radium 223 dicholoride Market by Value
3.2.8 Global Prostate Cancer Others Drug Market by Value

4. Regional Market Analysis
4.1 The US Prostate Cancer Market: An Analysis
4.1.1 The US Prostate Cancer Drug Market by Value
4.1.2 The US Prostate Cancer Market by Drug (Enzalutamide, Abiraterone acetate, Leuprorelin, Radium 223 dichloride, others)
4.1.3 The US Prostate Cancer Market by Volume
4.1.4 The US mCRPC Market by Volume
4.1.5 The US Prostate Cancer Second-Line Therapies Market by Volume
4.2 The US Prostate Cancer Market: Drug Analysis
4.2.1 The US Enzalutamide Market by Value
4.2.2 The US Abiraterone acetate Market by Value
4.2.3 The US Leuprorelin Market by Value
4.2.4 The US Radium 223 dichloride Market by Value
4.2.5 The US Cabazitaxel Market by Value
4.2.6 The US Prostate Cancer Others Drug Market by Value
4.3 China Prostate Cancer Market: An Analysis
4.3.1 China Prostate Cancer Drug Market by Value
4.3.2 China Prostate Cancer Market by Drug (Abiraterone acetate, Bicalutamide, Docetaxel, Leuprorelin, Goserelin, Triptorelin, Others)
4.3.3 China Prostate Cancer Market by Volume
4.3.4 China mCRPC Market by Volume
4.3.5 China mCRPC First-Line Treatment Market by Value
4.3.6 China mCRPC Second-Line Treatment Market by Value
4.3.7 China Prostate Cancer Second Line Therapies Market by Volume
4.4 China Prostate Cancer Market: Drug Analysis
4.4.1 China Abiraterone acetate Market by Value
4.4.2 China Bicalutamide Market by Value
4.4.3 China Docetaxel Market by Value
4.4.4 China Leuprorelin Market by Value
4.4.5 China Goserelin Market by Value
4.4.6 China Triptorelin Market by Value
4.4.7 China Prostate Cancer Other Drugs Market by Value

5. COVID-19
5.1 Impact of Covid-19 on Healthcare Industry
5.2 Impact of COVID-19 on Cancer Treatment
5.3 Impact of COVID-19 on Prostate Cancer Treatment

6. Market Dynamics
6.1 Growth Drivers
6.1.1 Increase in Prevalence of Prostate Cancer
6.1.2 Rise in Geriatric Population
6.1.3 Expanding Healthcare Costs
6.1.4 Rising Public Awareness towards Prostate Cancer Treatment
6.1.5 Altering Lifestyle
6.1.6 Availability of Generic Drugs
6.2 Challenges
6.2.1 Increasing Economic Burden of the Disease
6.2.2 Side-Effects Associated with Treatment
6.2.3 Overdiagnosis Issue
6.2.4 Loss of Patent Protection of Drugs
6.3 Market Trends
6.3.1 Increasing Use of Diverse Therapies
6.3.2 Approval of Novel Treatments and Drugs
6.3.3 Advances in Prostate Cancer Research

7. Competitive Landscape
7.1 The US Prostate Cancer Players’ Product Comparison
7.2 The US Prostate Cancer (mCRPC) Players’ Product Comparison
7.3 China Prostate Cancer Players’ Product Comparison
7.4 China Prostate Cancer (mCRPC) Players’ Product Comparison
7.5 China Other Types Prostate Cancer Players’ Product Comparison
7.6 mCRPC Drugs Clinical Trial Results Comparison

8. Company Profiles
8.1 Pfizer Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Johnson & Johnson
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Bayer AG
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 AstraZeneca
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy

List of Figures and Tables
Figure 1: Types of Cancer
Figure 2: Prostate Cancer Symptoms
Figure 3: Stages of Prostate Cancer
Figure 4: Types of Prostate Cancer
Figure 5: Global Prostate Cancer Drug Market by Value; 2015-2019 (US$ Billion)
Figure 6: Global Prostate Cancer Drug Market by Value; 2020-2024E (US$ Billion)
Figure 7: Global Prostate Cancer Market by Country; 2019 (Percentage, %)
Figure 8: Global Prostate Cancer Market by Drugs; 2019 (Percentage, %)
Figure 9: Global Enzalutamide Market by Value; 2015-2019 (US$ Billion)
Figure 10: Global Enzalutamide Market by Value; 2020-2024E (US$ Billion)
Figure 11: Global Abiraterone acetate Market by Value; 2015-2019 (US$ Billion)
Figure 12: Global Abiraterone acetate Market by Value; 2020-2024E (US$ Billion)
Figure 13: Global Leuprorelin Market by Value; 2015-2019 (US$ Billion)
Figure 14: Global Leuprorelin Market by Value; 2020-2024E (US$ Billion)
Figure 15: Global Goserelin Market by Value; 2015-2019 (US$ Billion)
Figure 16: Global Goserelin Market by Value; 2020-2024E (US$ Billion)
Figure 17: Global Cabazitaxel Market by Value; 2015-2019 (US$ Billion)
Figure 18: Global Cabazitaxel Market by Value; 2020-2024E (US$ Billion)
Figure 19: Global Bicalutamide Market by Value; 2015-2019 (US$ Billion)
Figure 20: Global Bicalutamide Market by Value; 2020-2024E (US$ Billion)
Figure 21: Global Radium 223 dicholoride Market by Value; 2015-2019 (US$ Billion)
Figure 22: Global Radium 223 dicholoride Market by Value; 2020-2024E (US$ Billion)
Figure 23: Global Others Drug Market by Value; 2015-2019 (US$ Billion)
Figure 24: Global Others Drug Market by Value; 2020-2024E (US$ Billion)
Figure 25: The US Prostate Cancer Drug Market by Value; 2015-2019 US$ Billion)
Figure 26: The US Prostate Cancer Drug Market by Value; 2020-2024E (US$ Billion)
Figure 27: The US Prostate Cancer Market by Drug; 2019 (Percentage, %)
Figure 28: The US Prostate Cancer Market by Volume; 2015-2019 (Million)
Figure 29: The US Prostate Cancer Market by Volume; 2020-2024E (Million)
Figure 30: The US mCRPC Market by Volume; 2015-2019 (Million)
Figure 31: The US mCRPC Market by Volume; 2020-2024E (Million)
Figure 32: The US Prostate Cancer Second-Line Therapies Market by Volume; 2015-2019 (Million)
Figure 33: The US Prostate Cancer Second-Line Therapies Market by Volume; 2020-2024E (Million)
Figure 34: The US Enzalutamide Market by Value; 2015-2019 (US$ Billion)
Figure 35: The US Enzalutamide Market by Value; 2020-2024E (US$ Billion)
Figure 36: The US Abiraterone acetate Market by Value; 2015-2019 (US$ Billion)
Figure 37: The US Abiraterone acetate Market by Value; 2020-2024E (US$ Billion)
Figure 38: The US Leuprorelin Market by Value; 2015-2019 (US$ Billion)
Figure 39: The US Leuprorelin Market by Value; 2020-2024E (US$ Billion)
Figure 40: The US Radium 223 dichloride Market by Value; 2015-2019 (US$ Billion)
Figure 41: The US Radium 223 dichloride Market by Value; 2020-2024E (US$ Billion)
Figure 42: The US Cabazitaxel Market by Value; 2015-2019 (US$ Billion)
Figure 43: The US Cabazitaxel Market by Value; 2020-2024E (US$ Billion)
Figure 44: The US Prostate Cancer Other Drugs Market by Value; 2015-2019 (US$ Billion)
Figure 45: The US Prostate Cancer Others Drug Market by Value; 2020-2024E (US$ Billion)
Figure 46: China Prostate Cancer Drug Market by Value; 2015-2019 (US$ Million)
Figure 47: China Prostate Cancer Drug Market by Value; 2020-2024E (US$ Million)
Figure 48: China Prostate Cancer Market by Drug; 2019 (Percentage, %)
Figure 49: China Prostate Cancer Market by Volume; 2015-2019 (Thousand)
Figure 50: China Prostate Cancer Market by Volume; 2020-2024E (Thousand)
Figure 51: China mCRPC Market by Volume; 2015-2019 (Thousand)
Figure 52: China mCRPC Market by Volume; 2020-2024E (Thousand)
Figure 53: China mCRPC First-Line Treatment Market by Value; 2015-2019 (US$ Million)
Figure 54: China mCRPC First-Line Treatment Market by Value; 2020-2024E (US$ Million)
Figure 55: China mCRPC Second-Line Treatment Market by Value; 2015-2019 (US$ Million)
Figure 56: China mCRPC Second-Line Treatment Market by Value; 2020-2024E (US$ Million)
Figure 57: China Prostate Cancer Second Line Therapies Market by Volume; 2015-2019 (Thousand)
Figure 58: China Prostate Cancer Second Line Therapies Market by Volume; 2020-2024E (Thousand)
Figure 59: China Abiraterone acetate Market by Value; 2015-2019 (US$ Million)
Figure 60: China Abiraterone acetate Market by Value; 2020-2024E (US$ Million)
Figure 61: China Bicalutamide Market by Value; 2020-2024E (US$ Million
Figure 62: China Bicalutamide Market by Value; 2020-2024E (US$ Million
Figure 63: China Docetaxel Market by Value; 2015-2019 (US$ Million)
Figure 64: China Docetaxel Market by Value; 2020-2024E (US$ Million)
Figure 65: China Leuprorelin Market by Value; 2015-2019 (US$ Million)
Figure 66: China Leuprorelin Market by Value; 2020-2024E (US$ Million)
Figure 67: China Goserelin Market by Value; 2015-2019 (US$ Million)
Figure 68: China Goserelin Market by Value; 2020-2024E (US$ Million)
Figure 69: China Triptorelin Market by Value; 2015-2019 (US$ Million)
Figure 70: China Triptorelin Market by Value; 2020-2024E (US$ Million)
Figure 71: China Prostate Cancer Other Drugs Market by Value; 2015-2019 (US$ Million)
Figure 72: China Prostate Cancer Other Drugs Market by Value; 2020-2024E (US$ Million)
Figure 73: Population Age 65 and above (% of Total population)
Figure 74: The US Health Expenditure (% of GDP)
Figure 75: Pfizer Revenue; 2015-2019 (US$ Billion)
Figure 76: XTANDI Revenue; 2018-2019 (US$ Million)
Figure 77: Pfizer Revenue by Segment; 2019 (Percentage, %)
Figure 78: Pfizer Revenue by Geography; 2019 (Percentage, %)
Figure 79: Johnson & Johnson Net Sales; 2015-2019 (US$ Billion)
Figure 80: Johnson & Johnson Net Sales by Segment; 2019 (Percentage, %)
Figure 81: Johnson & Johnson Net Sales by Geography; 2019 (Percentage, %)
Figure 82: Bayer AG Net Sales; 2015-2019 (US$ Billion)
Figure 83: Bayer AG Net Sales by Segments; 2019 (Percentage, %)
Figure 84: Bayer AG Net Sales by Geography; 2019
Figure 85: AstraZeneca Total Revenue; 2015-2019 (US$ Billion)
Figure 86: AstraZeneca Total Revenue by Product; 2019 (Percentage, %)
Figure 87: AstraZeneca Total Revenue by Region; 2019 (Percentage, %)
Table 1: Top 10 Countries with Highest Rates of Prostate Cancer; 2018
Table 2: 2nd generation AR antagonists approved for prostate cancer in US
Table 3: AR Antagonist Candidates for mCRPC in US
Table 4: 2nd Generation AR Antagonists for Prostate Cancer in China
Table 5: AR Antagonist Candidates for mCRPC in China
Table 6: AR Antagonist Candidates for Other Types of Prostate Cancer in China
Table 7: mCRPC Drugs Clinical Trial Results Comparison

Samples

Executive Summary

The global prostate cancer market has shown tremendous growth over the past few years and projections are made that the market would grow at a rapid pace over the forecasted period (2020-2024) as well. The aging population and altering lifestyle are the major factors contributed in the growth of market. Moreover, expanding healthcare cost, rising public awareness towards the disease, availability of generic drugs etc. would further augment market growth.

However, the market faces some challenges which are hindering the growth. Some of the major challenges faced by the industry are increasing economic burden of the disease, side-effects associated with treatment, over diagnosis issue etc. Though, the market growth would be further supported by various market trends like increasing use of diverse therapies, approval of novel treatments and drugs, advancements in prostate cancer research etc.

Companies Mentioned

• AstraZeneca
• Bayer AG
• Johnson & Johnson
• Pfizer Inc.